Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

April W Armstrong

Showing results (351-360 of 434) with videos related to

Pageof 44
Sort By:
Dermatology and Therapy|April 18, 2022
Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysisJonathan I Silverberg, H Chih-Ho Hong, Jacob P Thyssen, et al.
Dermatology and Therapy|July 30, 2024
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 22, 2022
A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30<sup>th</sup> EADV Congress 2021Andreas Pinter, Linda Stein Gold, Adam Reich, et al.
The Journal of Dermatology|November 11, 2024
Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysisTsen-Fang Tsai, Yayoi Tada, Camy Kung, et al.
The Journal of Rheumatology|May 3, 2020
Evaluation of Changes in Skin and Joint Outcomes and Associated Treatment Changes in Psoriatic Arthritis (PsA): Experience From the Corrona PsA/SpA RegistryPhilip J Mease, Carol J Etzel, William J Huster, et al.
The Journal of Dermatological Treatment|August 5, 2021
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE studyAndrew Blauvelt, April W Armstrong, Richard G Langley, et al.
Journal of Drugs in Dermatology : JDD|August 2, 2024
Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.
RMD Open|June 28, 2019
Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona RegistryPhilip J Mease, Carol J Etzel, William J Huster, et al.
Journal of Medical Internet Research|September 20, 2021
A Blueprint for the Conduct of Large, Multisite Trials in TelemedicinePatricia Commiskey, April W Armstrong, Tumaini R Coker, et al.
Journal of Dermatological Science|January 23, 2023
Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S studyAndrew Blauvelt, David M Pariser, Stephen Tyring, et al.
Pageof 44

Showing results (351-360 of 434) with videos related to

Sort By:
Pageof 44
Dermatology and Therapy|April 18, 2022
Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysisJonathan I Silverberg, H Chih-Ho Hong, Jacob P Thyssen, et al.
Dermatology and Therapy|July 30, 2024
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 22, 2022
A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30<sup>th</sup> EADV Congress 2021Andreas Pinter, Linda Stein Gold, Adam Reich, et al.
The Journal of Dermatology|November 11, 2024
Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysisTsen-Fang Tsai, Yayoi Tada, Camy Kung, et al.
The Journal of Rheumatology|May 3, 2020
Evaluation of Changes in Skin and Joint Outcomes and Associated Treatment Changes in Psoriatic Arthritis (PsA): Experience From the Corrona PsA/SpA RegistryPhilip J Mease, Carol J Etzel, William J Huster, et al.
The Journal of Dermatological Treatment|August 5, 2021
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE studyAndrew Blauvelt, April W Armstrong, Richard G Langley, et al.
Journal of Drugs in Dermatology : JDD|August 2, 2024
Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.
RMD Open|June 28, 2019
Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona RegistryPhilip J Mease, Carol J Etzel, William J Huster, et al.
Journal of Medical Internet Research|September 20, 2021
A Blueprint for the Conduct of Large, Multisite Trials in TelemedicinePatricia Commiskey, April W Armstrong, Tumaini R Coker, et al.
Journal of Dermatological Science|January 23, 2023
Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S studyAndrew Blauvelt, David M Pariser, Stephen Tyring, et al.
Pageof 44